US EditionPublished • loading... • Updated
US FDA Approves Vanda Pharmaceuticals' Motion ...
NEREUS showed vomiting risk reductions over 50% to 70% in pivotal trials, marking the first new motion sickness drug in 40 years, Vanda said.
- On Dec. 30, 2025, Vanda Pharmaceuticals Inc. announced FDA approval of NEREUS in Washington, expecting its launch in the coming months.
- Motion sickness arises from sensory conflict that triggers substance P release and NK-1 receptor activation, affecting about 25% to 30% of U.S. adults .
- Across the pivotal program, two Phase 3 boat provocation studies, Motion Syros and Motion Serifos, showed vomiting rates of 18.3%–19.5% and 10.4%–18.3%, with adverse reactions including somnolence and fatigue.
- Shares of Vanda Pharmaceuticals jumped after the approval, with the company stating Mihael H. Polymeropoulos called it "transformative"; market reaction remains to be seen.
- Vanda said it will advance tradipitant development programs for gastroparesis and GLP-1 receptor agonist–induced nausea and cautioned investors with forward-looking statements and risk disclosures.
Insights by Ground AI
68 Articles
68 Articles
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsFDA Greenlights First Motion Sickness Drug in More Than 40 Years
(MedPage Today) -- The FDA approved tradipitant (Nereus), an oral neurokinin-1 (NK-1) receptor antagonist, to prevent vomiting induced by motion in adults, Vanda Pharmaceuticals announced Tuesday. The approval marks the first new drug treatment...
·New York, United States
Read Full Article
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Eli Lilly (NYSE:LLY), Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals' shares surged in after-hours trading following FDA approval of NEREUS for preventing motion-induced vomiting in adults.
·New York, United States
Read Full Article
The Berkshire Eagle+59 Reposted by 59 other sources
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion.…
Coverage Details
Total News Sources68
Leaning Left8Leaning Right3Center26Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 22%
C 70%
Factuality
To view factuality data please Upgrade to Premium
